Related Experiment Videos
Development of the phenylketonuria screening programme in Estonia
K Ounap1, H Lilleväli, A Metspalu
1Medical Genetics Center, Tartu University Children's Hospital, Estonia.
Journal of Medical Screening
|May 12, 1998
Summary
Estonia established newborn screening for phenylketonuria (PKU) in 1993. The program identified a birth prevalence of classic PKU higher than the European average, indicating a need for continued monitoring.
Area of Science:
- Medical Genetics
- Public Health
- Neonatal Screening
Background:
- Phenylketonuria (PKU) is a rare genetic disorder.
- Effective newborn screening programs are crucial for early diagnosis and management.
- Estonia aimed to establish a robust PKU screening program.
Purpose of the Study:
- To develop and implement a phenylketonuria (PKU) screening program in Estonia.
- To determine the birth prevalence of PKU in the Estonian population.
Main Methods:
- Retrospective data collection of PKU patients born between 1980-1992.
- Prospective newborn screening using a modified fluorometric phenylalanine assay from 1993-1995.
- Screening covered 85% of newborns during the study period.
Main Results:
- Six cases of classical PKU were diagnosed in 36,074 screened newborns (1993-1995).
- No mild hyperphenylalaninemia cases were detected.
- Retrospective incidence: 1 in 8090; Prospective incidence: 1 in 6010 live births.
Conclusions:
- The birth prevalence of classical PKU in Estonia is higher than the European average.
- The prevalence is comparable to some Eastern and Middle European countries.
- The developed screening program effectively identified PKU cases.